Firefly Bio is a biotechnology company developing the Firelink degrader antibody conjugate platform, designed to deliver targeted protein degraders directly to cancer cells to treat difficult-to-address solid tumors.
Johnson & Johnson acquired Firefly Bio for $1 billion in cash, gaining a novel technology intended to selectively target KRAS-driven cancers and other hard-to-treat malignancies while preserving healthy tissue.
GroveStreet first became a Versant Ventures LP in 2018. Read more here.
Learn more about us or reach out to schedule a meeting.